NEW YORK, June 15, 2006 (PRIMEZONE) -- Seeger Weiss LLP announces that it is investigating claims involving various pharmaceuticals in the class of ACE inhibitors for potentially related birth injuries, including reports of heart defects, gastrointestinal problems, and central nervous system defects.
ACE inhibitors comprise a class of drugs that inhibit an enzyme responsible for constricting blood vessels. Common ACE inhibitors include Capoten, Vasotec, Prinivil/Zestril, Lotensin, Monopril, Altace, Accupril, Aceon, Mavik, and Univasc. They are typically prescribed to regulate high blood pressure. A national survey indicated that 2.7 million women of childbearing age were prescribed an ACE inhibitor in 2002, and total prescriptions in 2005 reached 150 million.
Recently, the New England Journal of Medicine has reported that ACE inhibitors may cause birth defects when taken by pregnant women in their first trimester. ACE inhibitors are already associated with an increased risk of birth defects when used in the second and third trimester, but this study is the first to show a possible earlier risk. Indications from two studies show that women who take ACE inhibitors during the first trimester of pregnancy may be approximately three times as likely to have a child with a birth defect when compared to mothers who were not on the medications.
If you have taken an ACE inhibitor and experienced any of the aforementioned side-effects, please visit http://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/ACE-Inhibitors-P136/ or call (877) 541-3273 to request a free evaluation.
About Seeger Weiss LLP
Seeger Weiss (www.seegerweiss.com) is a New York based law firm that is active in major complex litigations, including pharmaceutical mass tort and product defect cases pending in federal and state courts throughout the United States. Seeger Weiss has taken a leading role in many important actions on behalf of injured consumers and has successfully recovered millions of dollars for individual clients and class members. For example, Seeger Weiss currently serves as Court Appointed Co-Lead Counsel in the federal Vioxx Litigation (http://www.seegerweiss.com/cases/Cases.aspx?ID=24) and was one of the lead firms that negotiated the recently announced $700 million settlement of claims on behalf of individuals who were injured as a result of their use of the prescription drug Zyprexa (http://www.seegerweiss.com/cases/Cases.aspx?ID=27).
If you or a family member is using or has used an ACE inhibitor drug and would like to discuss your rights, or if you have information concerning the potential adverse consequences associated with the use of these drugs that you would like to share with us, please contact us:
Christopher A. Seeger, Esq.
http://www.lawyerseek.com/Attorneys/Christopher-A-Seeger-Partners-E3.html
David R. Buchanan, Esq.
http://www.lawyerseek.com/Attorneys/David-R-Buchanan-Partners-E6.html
Seeger Weiss LLP
One William Street
New York, New York 10004
E-Mail: cseeger@seegerweiss.com
dbuchanan@seegerweiss.com
Tel: (212) 584-0700
Toll Free: (877) 541-3273
www.seegerweiss.com, www.lawyerseek.com
To submit a claim for review please visit: http://www.lawyerseek.com/Practice/Pharmaceutical-Injury-C1/ACE-Inhibitors-P136/